Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ARQT, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
ARQT reported $238.6M in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ARQT files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Rubric Capital Management LP | Institution (13G, 5%+) | 8,271,577 | 6.58% | 2025-12-31 |
| Polar Capital Holdings Plc | Institution (13G, 5%+) | 6,606,945 | 5.26% | 2026-06-30 |
| Todd Watanabe Reporting Person's title: President and · +266,000 options |
Insider | 899,517 | 0.72% | 2026-08-03 |
| Christopher Peetz Director · +13,010 options |
Insider | 187,500 | 0.15% | 2026-07-15 |
| Larry Todd Edwards Reporting Person's title: EVP, Chief Com · +77,000 options |
Insider | 175,178 | 0.14% | 2026-02-27 |
| Patrick Burnett Reporting Person's title: EVP, Chief Med · +205,750 options |
Insider | 117,592 | 0.09% | 2026-08-19 |
| Masaru Matsuda Reporting Person's title: EVP, Chief Leg · +97,000 options |
Insider | 112,508 | 0.09% | 2026-09-16 |
| Latha Vairavan SVP Chief Financial Officer · +70,000 options |
Insider | 85,978 | 0.07% | 2026-05-11 |
| Howard G. Welgus Director · +49,417 options |
Insider | 35,841 | 0.03% | 2026-09-15 |
| Keith R Leonard Director · +16,667 options |
Insider | 29,651 | 0.02% | 2026-06-05 |
| Neha Krishnamohan Director · +16,667 options |
Insider | 27,901 | 0.02% | 2026-06-05 |
| Halley E Gilbert Director · +16,667 options |
Insider | 27,901 | 0.02% | 2026-06-05 |
Share count 125,691,961 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2025-10-13 | — | sNDA | +13.3% | +3.3% | +4.1% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ARQT and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →